Kimberly L. Garrison

Author

Gilead Sciences (United States)

Also Known As

K.L. Garrison, Kimberly L. Garrison

Publications

675

Citations

H-Index

Concepts

All Affiliations

Gilead Sciences (United States)University of Ulsan University of California, San Francisco Ulsan College Asan Medical Center

About

Kimberly L. Garrison is an author at Gilead Sciences (United States) specializing in medicine, hepatitis, and viral hepatitis.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	5	5	558
2	Hepatology	3	3	495
3	Immunology	1	1	183
4	Pharmacology	1	1	43
5	Autoimmune Disease	1	1	183

Kimberly L. Garrison

Publications

599

Citations

H-Index

Page 1

	Year	Citations
Sofosbuvir plus ribavirin in Japanese patients with chronic genotype 2 <scp>HCV</scp> infection: an open‐label, phase 3 trial Masao Omata, Shuhei Nishiguchi, Yoshiyuki Ueno, Journal of Viral Hepatitis Japanese PatientsHcv InfectionHepatologyHepatitis CViral Hepatitis	2014	201
The oral toll-like receptor-7 agonist GS-9620 in patients with chronic hepatitis B virus infection Edward Gane, Young‐Suk Lim, Stuart C. Gordon, Journal of Hepatology Autoimmune DiseaseHepatologyViral HepatitisImmunologyHepatitis B	2015	183
Safety and Efficacy of Ledipasvir–Sofosbuvir With or Without Ribavirin for Chronic Hepatitis C in Children Ages 6‐11 Karen F. Murray, William F. Balistreri, Sanjay Bansal, Hepatology Hcv GenotypeHepatic DisordersHepatologyHepatitis CViral Hepatitis	2018	111
Few Drugs Display Flip-Flop Pharmacokinetics and These Are Primarily Associated with Classes 3 and 4 of the BDDCS Kimberly L. Garrison, Selma Şahin, Leslie Z. Benet Journal of Pharmaceutical Sciences Classes 3PharmacologyPharmacotherapyAre Primarily AssociatedMedicine	2015	43
Ledipasvir/sofosbuvir fixed‐dose combination tablet in Taiwanese patients with chronic genotype 1 hepatitis C virus Wan‐Long Chuang, Rong‐Nan Chien, Cheng‐Yuan Peng, Journal of Gastroenterology and Hepatology	2016	27
A phase IIIb study of ledipasvir/sofosbuvir fixed-dose combination tablet in treatment-naïve and treatment-experienced Korean patients chronically infected with genotype 1 hepatitis C virus Young‐Suk Lim, Sang Hoon Ahn, Kwan Sik Lee, Hepatology International Hepatitis CHepatitis C VirusViral HepatitisAntiviral Drug DevelopmentHepatitis B	2016	20
Organic Anion Transporting Polypeptide Inhibition Dramatically Increases Plasma Exposure but not Pharmacodynamic Effect nor Inferred Hepatic Intracellular Exposure of Firsocostat Brian J. Kirby, Justin D. Lutz, Mun Sang Yue, Clinical Pharmacology & Therapeutics	2020	14

Page 1